ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Creative Biolabs Advances Neuroscience Research with Advanced iPSC-Derived Neural Cell Services

By: Get News
Creative Biolabs has openly announced a breakthrough in stem cell research, now offering a comprehensive set of services to derive neural cells from human induced pluripotent stem cells (iPSCs).

New York, USA - October 27, 2025 - Obtaining functionally stable human neurons has been a pivotal problem for neuroscience research. Creative Biolabs offers custom neural differentiation services, providing a powerful approach to addressing the problem. The firm uses cutting-edge stem cell technology to reprogram clients' provided somatic cells into iPSCs and efficiently differentiate them into numerous specific neural cell types, including dopaminergic neurons, motor neurons, and astrocytes.

"Our platform does not simply provide cells; it provides research opportunities," said a senior scientist at Creative Biolabs. "With iPSCs derived from patient cells, we can create highly predictive disease models. This enables researchers to directly observe the formation and progression of diseases in a petri dish and do efficacy testing of potential drugs."

Based on its advanced neural differentiation technology, Creative Biolabs has introduced a portfolio of off-the-shelf neural cell products, including hiPSC-derived GABAergic neurons. As the major inhibitory neurons in the central nervous system, GABAergic neurons are correlated with many neurological and psychiatric disorders. The GABAergic neurons provided by the company are highly pure and functionally robust, having also undergone thorough quality control to ensure their electrophysiological activity and neurotransmitter release closely resemble that of in vivo neurons.

These expert services in the field of neuroscience are a component of Creative Biolabs' comprehensive, customized iPSC-derived cell service system. The company's overall solution includes the whole process from the creation of iPSC lines, directed differentiation, to functional validation, not only for the nervous system, but also including preparation of various significant cell types such as cardiomyocytes and hepatocytes, which together provide a solid foundation for drug screening, toxicity assays, and regenerative medicine research.

A spokesperson of the company further stated, "We strive to break the limitations of traditional research paradigms. By combining customized differentiation services with off-the-shelf cell products, we provide the scientific community with a nimble and powerful toolkit to help them unlock the secrets of life with unparalleled depth and precision."

Learn more, please visit https://neuros.creative-biolabs.com.

About Creative Biolabs

Creative Biolabs is a global leader in the biotechnology industry, dedicated to providing high-quality, customized products and services to the biopharmaceutical and academic research communities. Equipped with extensive technical knowledge in stem cell technology, antibody engineering, and drug discovery, Creative Biolabs continues to provide innovative solutions to the world, driving advancements in the life sciences.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://neuros.creative-biolabs.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.41
+1.37 (0.56%)
AAPL  268.47
-1.30 (-0.48%)
AMD  233.54
-4.16 (-1.75%)
BAC  53.20
-0.09 (-0.17%)
GOOG  279.70
-5.64 (-1.98%)
META  621.71
+2.77 (0.45%)
MSFT  496.82
-0.28 (-0.06%)
NVDA  188.15
+0.07 (0.04%)
ORCL  239.26
-4.54 (-1.86%)
TSLA  429.52
-16.39 (-3.68%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.